A rare study that examines the benefits of dual SGLT2i and GLP1 therapy. On paper, it makes sense to combine them since they reduce CVD risk by mostly indpendent pathways. This study shows that under inflamatory conditions in certain organs, both compounds work synergistically, and they explain why: SGLT2i block downregulation of GLP1 receptors, which allows GLP1 receptor agonists to work better.
https://www.jacc.org/doi/10.1016/j.jacbts.2026.101587
AI Summary
Overview and Objective
Atrial Fibrillation (AF) is a common heart rhythm disorder that is heavily driven by chronic inflammation, oxidative stress, and tissue scarring (fibrosis) in the upper chambers of the heart. While SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) are widely praised in metabolic and longevity medicine for their cardiovascular and anti-inflammatory benefits, their exact roles in direct heart tissue remodeling remain less defined.
This study aimed to:
Determine how SGLT2 and GLP-1 receptors are expressed in human atrial tissue during inflammation.
Test whether combining low doses of an SGLT2i (empagliflozin) and a GLP-1RA (semaglutide) offers a synergistic protective effect against inflammation-induced oxidative stress in the heart.
Experimental Model & Design
The researchers evaluated both human cardiac tissue samples and isolated cell models:
Human Tissue Samples: 80 right atrial appendage (RAA) tissue samples were collected from patients undergoing cardiac surgery (18 with a history of AF and 62 in normal sinus rhythm).
Cell Culture Models: To pinpoint specific cellular pathways, tests were run on human coronary artery endothelial cells (lining blood vessels), AC16 cardiomyocytes (heart muscle cells), and peripheral blood mononuclear cells (PBMCs/immune cells).
Testing Protocol: Tissues and cells were exposed to the inflammatory cytokine Tumor Necrosis Factor-alpha (TNF-alpha). The researchers then applied SGLT2i, GLP-1RA, or a combination of both to measure reactive oxygen species (ROS / free radicals) and markers of tissue remodeling and fibrosis.
Key Findings
AF is linked to higher inflammation: Tissue from AF patients showed significantly higher oxidative stress, structural fibrosis, and pro-inflammatory markers compared to non-AF controls.
Receptor Upregulation in Inflamed Tissue: In inflamed atrial tissue, expression of both SGLT2 and GLP-1 receptors was markedly increased. SGLT2 was primarily elevated in endothelial cells and macrophages, whereas GLP-1 receptors were mainly elevated in cardiomyocytes and macrophages.
Single Therapies Help: Individually, both empagliflozin (SGLT2i) and semaglutide (GLP-1RA) reduced ROS levels in highly inflamed RAA tissues.
Dual Therapy is Synergistic: When given together at low doses (10 nM each) —concentrations that had minimal impact on their own—the combination dramatically suppressed ROS (reducing it by ~42%), matching the strength of heavy-duty antioxidant treatments.
Mechanism of Synergistic Benefit
The combination of an SGLT2i and a GLP-1RA works better than either drug alone due to complementary targeting and cellular crosstalk:
Cell-Specific Targeting: SGLT2i primarily targets pro-oxidant pathways in endothelial cells and recruited macrophages, while GLP-1RAs act on heart muscle cells (cardiomyocytes) and macrophages via the cAMP/PKA pathway. Combining them addresses oxidative stress across all major tissue compartments simultaneously.
Receptor Crosstalk: Under inflammatory conditions (like high TNF-$\alpha$), GLP-1 receptors in endothelial cells are normally suppressed/downregulated. Inhibiting or knocking down SGLT2 blocks this downregulation, allowing GLP-1RAs to remain active and functional in the blood vessels.
Other Studies Showing Similar Results
The authors cite several observational and clinical studies reflecting similar benefits:
Cardiovascular Events: Population-based cohort studies and clinical trials (such as SUSTAIN 9) demonstrate that combining GLP-1RAs and SGLT2i reduces major adverse cardiovascular events in diabetic patients by roughly 30% compared to monotherapy.
Atrial Remodeling & AF Recurrence: Clinical studies on GLP-1RAs (e.g., STEP-HFpEF program with semaglutide) and SGLT2i meta-analyses show that both drug classes individually improve left atrial structure and lower AF recurrence after catheter ablation.
Strengths and Weaknesses
Strengths
Direct Human Relevance: Uses actual human cardiac tissue (RAAs) taken directly during surgery rather than relying solely on animal models.
Multi-Level Validation: Combines tissue-level staining, single-cell analysis, gene expression, and targeted cell culture experiments to build a cohesive mechanistic model.
Methodological Rigor: Applied Inverse Probability of Treatment Weighting (IPTW) to balance baseline clinical differences between patient groups.
Weaknesses
Sample Size & Tissue Focus: Small patient cohort ($N=80$, with only 18 AF patients). Furthermore, RAA tissue was used, whereas AF primarily affects the left atrium and left atrial appendage.
Tissue vs. Clinical Dosing: The 10 nM laboratory concentrations used to show synergy may not directly translate to standard clinical plasma or heart tissue exposure levels.
Lack of Electrophysiology: The study evaluated structural remodeling, inflammation, and ROS, but did not directly test the electrical properties or arrhythmias of the heart tissue.
1 Like